Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Efficacy for glycemic control : Clinical trials of semaglutide (SUSTAIN program) have demonstrated hemoglobin A1c reductions of 1.5-2.0% in patients with type 2 diabetes, with many patients achieving A1c levels below 7%
Alfradi Mulihano, Clare OBrien, MD
Semaglutide (Wegovy) for the treatment of obesity
The gut lining can take a beating during extended use of GLP-1 class medications, and some researchers believe that supporting gut integrity proactively leads to better long-term tolerance
US$ 20.35
US$ 27.17
US$ 28.09
